top of page
Our Strategy
Utilizing biological mediators and pathways, FibroGen is accelerating a pipeline of treatments focusing on cancer and its related conditions.
Our near-term strategies include:
-
Completion of two late-stage pivotal studies of pamrevlumab in pancreatic cancer.
-
Progression of supplemental new drug application filed with the China Health Authority by FibroGen and our partner AstraZeneca for roxadustat in patients with chemotherapy-induced anemia with an expected approval decision in mid-2024.
-
Initiation of a Phase II trial of FG-3246 for metastatic castration-resistant prostate cancer in the second half of 2024.
-
Accelerating our early-stage oncology pipeline.
-
Continued market growth of roxadustat in China.
bottom of page